Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Percutaneous tibial nerve stimulation effective in patients with overactive bladder

24 Jan 2020

The efficacy and compliance related to percutaneous tibial nerve stimulation (PTNS) are both favourable in traditionally underserved patients treated for overactive bladder at a large urban safety net hospital, reports a study.

Fifty patients (mean age, 59 years; 80 percent black; 52 percent male) were included in the analysis, of whom 34 percent were not insured and 54 percent had government insurance. Prior treatment included behavioural modification in 100 percent of patients, anticholinergics in 86 percent and mirabegron in 4 percent. Participants completed a mean of 10.7 of the 12 planned weekly PTNS treatments.

Seventy percent of the patients completed all 12 weekly treatments. Of these, 77 percent continued to maintenance treatment. Average symptoms improved across all metrics following PTNS treatment, including mean daytime frequency (from 11.0 to 6.6 episodes per day; –24.5 percent), night-time frequency (from 4.8 to 2.5 episodes per night; –47.1 percent), urgency score (from 3.4 to 1.9; –42.1 percent) and incontinence (from 1.6 to 0.4 episodes per day; –79.6 percent; p-each<0.001).

Forty-three of the 50 patients (86 percent) reported symptom improvement.

“[PTNS treatment] should be considered as a feasible modality to manage overactive bladder symptoms in patients in a similar demographic,” the authors said.

The study recruited consecutive patients who underwent PTNS at Grady Memorial Hospital from May 2015 through January 2019 and reviewed their records retrospectively. Self-reported urinary symptoms and episodes of urinary incontinence were the primary outcomes. Secondary outcome was patient compliance, defined as completion of 12 treatment sessions. The authors conducted descriptive analysis as well as paired t-tests.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.